Detection of lupus anticoagulant in the presence of rivaroxaban using Taipan snake venom time

Journal of Thrombosis and Haemostasis

Volumn 9, Issue 8, 2011, Pages 1657-1659

  van Os, G M A ^a,b   de Laat, B ^a,c,d   Kamphuisen, P W ^b   Meijers, J C M ^b   de Groot, Ph G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; LUPUS ANTICOAGULANT; RIVAROXABAN; SNAKE VENOM;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING TEST; CLINICAL ARTICLE; DRUG EFFICACY; HUMAN; LABORATORY TEST; LETTER; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOSIS PREVENTION; TIME;

ANIMALS; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CASE-CONTROL STUDIES; ENDOPEPTIDASES; HUMANS; LUPUS COAGULATION INHIBITOR; MORPHOLINES; PEPTIDE HYDROLASES; PREDICTIVE VALUE OF TESTS; PROTHROMBIN; THIOPHENES; TIME FACTORS;

EID: 80051595884     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2011.04395.x     Document Type: Letter

References (12)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RHWM, de Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. 2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 2005; 105: 1540-5.
3. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-32.
4. Derksen RHWM, de Groot PG. Towards evidence-based treatment of thrombotic antiphospholipid syndrome. Lupus 2010; 19: 470-4.
5. Ruiz-Irastorza G, Cuadrado M, Ruiz-Arruza I, Brey R, Crowther M, Derksen RHWM, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-18.
6. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 - an oral, direct factor Xa inhibitor - after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005; 61: 873-80.
7. Cohen H, Machin SJ. Antithrombotic treatment failures in antiphospholipid syndrome: the new anticoagulants. Lupus 2010; 19: 486-91.
8. Graff J, von Hentig N, Misselwitz F, Kubitza D, Becka M, Breddin HK, Harder S. Effects of the oral, direct factor Xa inhibitor rivaroxaban on platelet-induced thrombin generation and prothrombinase activity. J Clin Pharmacol 2007; 47: 1398-407.
9. Moore GW, Smith MP, Savidge GF. The ecarin time is an improved confirmatory test for the taipan snake venom time in warfarinized patients with lupus anticoagulant. Blood Coagul Fibrinolysis 2003; 14: 307-12.
10. Pengo V, Tripodi A, Reber G, Rand JH, Ortel TL, Galli M, De Groot PG. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. J Thromb Haemost 2009; 7: 1737-40.
11. Merriman E, Kaplan Z, Butler J, Malan E, Gan E, Tran H. Rivaroxaban and false positive lupus anticoagulant testing. Thromb Haemost 2010; 105: 385-6.
12. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol 1993; 100: 94-8.